Award
National Institute of Allergy and Infectious Diseases 1U01AI195194-01
AMS05: Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
Recipient
University of Pennsylvania, Philadelphia, PA, United States
Award Amount
$1,336,625.00
Ceiling
$1,336,625.00
Awarded
June 19, 2026
Identifier
1U01AI195194-01
A clinical trial funded by NIH to test discontinuation of anti-CD20 therapy in relapsing multiple sclerosis patients, aiming to identify biomarkers and mechanisms of remission and disease breakthrough.
Description
The project involves a clinical trial testing discontinuation of anti-CD20 therapy in MS. The study aims to identify biomarkers and mechanisms underlying remission and disease breakthrough. The trial includes frequent MRI and biosampling.